Agenus vs Mesoblast
Agenus and Mesoblast are similar in size: $114m and $120m of revenue in their latest fiscal years. Mesoblast grew faster (599.2% against 10.4%). Agenus kept more of each dollar of sales as profit: a net margin of -0.1% against -47.8%.
| Latest fiscal year | AgenusAGEN, 2025 | MesoblastMESO, 2026 |
|---|---|---|
| Revenue | $114m | $120m |
| Revenue growth | 10.4% | 599.2% |
| Net income | −$101,000 | −$57.5m |
| Operating margin | -17.7% | — |
| Net margin | -0.1% | -47.8% |
| Return on equity | — | -9.9% |
| Free cash flow | −$77.2m | −$44.7m |
| Cash | $3.0m | $103m |
| Total debt | $45.5m | $130m |
| Debt to equity | — | 22.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 81 | — |
| Market value | $284m | $1.91bn |
| Price vs our value range | — | — |
| Moat score | 34 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 24 buys, 0 sales |